Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

Rhea-AI Summary

Attovia Therapeutics (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases, began trading on Nasdaq on August 5, 2026 Beijing time. The IPO was priced at $17.00 per share and opened at $21.00, implying an approximate market capitalization of $904 million.

Founded in 2023, Attovia discovers all its product candidates on its ATTOBODY biologics platform, licensed exclusively worldwide from Alamar Biosciences. The platform supports rapid discovery of mono‑, bi‑ and trispecific biologics. IPO proceeds will mainly fund clinical development of lead candidates ATTO‑1310, ATTO‑2306 and research on ATTO‑1091, alongside other corporate purposes.

Positive

• Nasdaq listing completed with IPO price $17 and $21 opening
• Approximate market capitalization of $904 million at debut
• IPO proceeds earmarked to advance ATTO‑1310, ATTO‑2306 and ATTO‑1091 pipeline
• Exclusive worldwide license to ATTOBODY platform from Alamar Biosciences

Negative

• None.

Market Context

Short interest was 0.61%, categorized as low, adding limited short-positioning context to this Nasda...

Analysis

Short interest was 0.61%, categorized as low, adding limited short-positioning context to this Nasdaq IPO. The principal watchpoint is execution across the three named candidates, with no sourced clinical or financial outcome reported.

Key Figures

IPO issue price: $17.00 per share Opening price: $21.00 per share Market capitalization: $904 million +3 more

6 metrics

IPO issue price $17.00 per share Nasdaq listing

Opening price $21.00 per share Nasdaq listing

Market capitalization $904 million At listing

Listing date August 5, 2026 Beijing time

Operations commenced 2023 Company commencement of operations

Product candidates 3 product candidates ATTO-1310, ATTO-2306 and ATTO-1091

Key Terms

ipo, monospecific, bispecific, trispecific, +1 more

5 terms

ipo financial

"issued shares at a price of $17.00 per share"

An initial public offering (IPO) is the process by which a private company sells its shares to the public for the first time, making its ownership available on the stock market. This allows the company to raise money from a wide range of investors to fund growth or other goals. For investors, an IPO offers a chance to buy into a company early in its public journey, potentially benefiting if the company grows in value.

View in glossary

monospecific medical

"assembled into monospecific, bispecific and trispecific biologics"

Monospecific describes a medical or biological product, test, or molecule that targets or reacts with a single specific biological entity—such as one species, one antigen, or one molecular site—rather than multiple targets. For investors, it signals a focused mechanism of action and a narrower development and regulatory profile; think of it like a key cut to fit one particular lock, which can simplify manufacturing and clinical testing but also limits the range of applications.

bispecific medical

"assembled into monospecific, bispecific and trispecific biologics"

A bispecific molecule is a therapeutic designed to bind two different biological targets at once — imagine a two-headed key that fits two locks simultaneously. For investors, bispecific therapies matter because that dual-action can make a treatment more effective or selective, potentially improving clinical results, altering safety profiles, and creating a stronger commercial edge; those factors directly affect development risk, regulatory chances, and future revenue prospects.

trispecific medical

"assembled into monospecific, bispecific and trispecific biologics"

A trispecific drug is a single engineered molecule designed to attach to three different biological targets at once, like a three-pronged tool that can grip multiple pieces simultaneously. For investors, trispecifics can offer greater therapeutic precision or combined effects compared with single-target drugs, potentially boosting value if successful, but they also bring higher scientific complexity, development cost and regulatory risk.

high-throughput technical

"an evolution-based high-throughput workflow"

High-throughput describes methods, instruments, or workflows designed to process, test or analyze very large numbers of samples or data points quickly and often automatically. For investors, it matters because higher throughput can cut the time and cost to develop products, scale operations, and generate results that drive regulatory approvals or sales—think of it like switching from one checkout lane to an automated bank of many lanes that serve customers much faster.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00 per share and opened at $21.00 per share, with an approximate market capitalization of $904 million.

Commencing operations in 2023, Attovia develops next‑generation biotherapeutics for immune‑mediated diseases with high unmet medical needs. All of Attovia's product candidates are discovered on its ATTOBODY biologics platform, which is licensed under an exclusive worldwide license from Alamar Biosciences, also a portfolio company of Qiming Venture Partners. Leveraging an evolution‑based high‑throughput workflow, the platform enables rapid discovery of highly diverse candidates that can be assembled into monospecific, bispecific and trispecific biologics.

Leveraging the ATTOBODY platform, Attovia has nominated three product candidates: ATTO‑1310, ATTO‑2306 and ATTO‑1091. As disclosed in the prospectus, proceeds from this IPO will mainly be used to advance the clinical development of ATTO‑1310, ATTO‑2306 and the research pipeline including ATTO‑1091, among other purposes.

Dr. Kan Chen, Partner and Healthcare Co-Lead at Qiming Venture Partners, commented: "Immune‑mediated diseases affect large patient populations worldwide and substantial unmet clinical needs persist with current standard‑of‑care therapies. Attovia's differentiated ATTOBODY platform, in‑licensed from Alamar Biosciences, provides a powerful engine for engineering complex multi‑specific biologics. Qiming Venture Partners maintains a long‑term focus on investing in pioneering‑innovation biotech companies. We backed Attovia at its early stage and witnessed the team advance platform technology into clinical‑stage assets. Proceeds from this Nasdaq IPO will strongly support further advancement of its core pipeline. We look forward to Attovia delivering novel therapeutics to benefit patients globally."

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

View original content:https://www.prnewswire.com/news-releases/immune-mediated-disease-therapeutics-developer-attovia-therapeutics-debuts-on-nasdaq-302844859.html

SOURCE Qiming Venture Partners

FAQ

What happened during Attovia Therapeutics' (ATTO) Nasdaq debut on August 5, 2026?

Attovia Therapeutics began trading on Nasdaq on August 5, 2026 Beijing time. According to Attovia Therapeutics, shares were issued at $17.00, opened at $21.00 per share and reflected an approximate $904 million market capitalization at listing.

At what price was Attovia Therapeutics (ATTO) IPO priced and how did it open?

Attovia Therapeutics priced its Nasdaq IPO at $17.00 per share and opened at $21.00. According to Attovia Therapeutics, this trading debut corresponded to an approximate market capitalization of $904 million, signaling initial investor interest above the issue price.

How will Attovia Therapeutics (ATTO) use its Nasdaq IPO proceeds?

Attovia plans to use IPO proceeds mainly to advance ATTO‑1310 and ATTO‑2306 and support its broader research pipeline. According to Attovia Therapeutics, funds will also help progress ATTO‑1091 and be applied to other general corporate purposes as disclosed.

What does Attovia Therapeutics (ATTO) develop and when did it start operations?

Attovia develops next‑generation biotherapeutics for immune‑mediated diseases with high unmet medical needs. According to Attovia Therapeutics, the company commenced operations in 2023 and focuses on product candidates discovered exclusively on its ATTOBODY biologics platform licensed from Alamar Biosciences.

What is the ATTOBODY platform used by Attovia Therapeutics (ATTO)?

ATTOBODY is a biologics platform enabling rapid discovery of highly diverse therapeutic candidates for immune‑mediated diseases. According to Attovia Therapeutics, this evolution‑based high‑throughput system can generate mono‑, bi‑ and trispecific biologics and is licensed under an exclusive worldwide agreement from Alamar Biosciences.

Which pipeline programs are prioritized after the Attovia Therapeutics (ATTO) IPO?

Attovia is prioritizing ATTO‑1310, ATTO‑2306 and ATTO‑1091 following its Nasdaq IPO. According to Attovia Therapeutics, proceeds will mainly support clinical development of ATTO‑1310 and ATTO‑2306 and continue research on ATTO‑1091, alongside funding additional corporate purposes.